See more : ATN International, Inc. (ATNI) Income Statement Analysis – Financial Results
Complete financial analysis of MeiraGTx Holdings plc (MGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MeiraGTx Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Oconee Financial Corporation (OSBK) Income Statement Analysis – Financial Results
- KION GROUP AG (KIGRY) Income Statement Analysis – Financial Results
- Golden Arrow Merger Corp. (GAMC) Income Statement Analysis – Financial Results
- Vasundhara Rasayans Limited (VRL.BO) Income Statement Analysis – Financial Results
- Po Valley Energy Limited (PVE.AX) Income Statement Analysis – Financial Results
MeiraGTx Holdings plc (MGTX)
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.02M | 15.92M | 37.70M | 15.56M | 13.29M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 8.72M | 7.87M | 0.00 | 0.00 | 2.05M | 679.18K | 243.08K |
| Gross Profit | 14.02M | 7.20M | 29.83M | 15.56M | 13.29M | -2.05M | -679.18K | -243.08K |
| Gross Profit Ratio | 100.00% | 45.21% | 79.12% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.79M | 85.73M | 67.13M | 33.91M | 24.88M | 33.62M | 22.36M | 14.04M |
| General & Administrative | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Other Expenses | 0.00 | 361.00K | -434.00K | 0.00 | 0.00 | 83.08K | -553.50K | 0.00 |
| Operating Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Cost & Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Interest Income | 2.27M | 777.00K | 212.00K | 1.28M | 370.60K | 53.41K | 26.07K | 32.07K |
| Interest Expense | 13.25M | 4.95M | 288.00K | 139.20K | 48.61K | 33.43K | 42.86K | 25.44K |
| Depreciation & Amortization | 13.73M | 8.72M | 7.87M | 4.17M | 3.35M | 2.05M | 679.18K | 243.08K |
| EBITDA | -57.05M | -115.95M | -71.40M | -53.68M | -51.35M | -78.10M | -31.01M | -19.82M |
| EBITDA Ratio | -407.02% | -725.99% | -193.58% | -393.75% | -435.58% | 0.00% | 0.00% | 0.00% |
| Operating Income | -137.06M | -116.36M | -73.19M | -62.55M | -58.27M | -78.10M | -31.68M | -20.06M |
| Operating Income Ratio | -977.82% | -730.87% | -194.14% | -401.94% | -438.37% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 53.03M | -13.26M | -6.37M | 4.56M | 3.52M | -5.24M | 640.19K | 272.17K |
| Income Before Tax | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -83.34M | -31.04M | -19.79M |
| Income Before Tax Ratio | -599.46% | -814.16% | -211.03% | -372.63% | -411.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.26M | -7.59M | -4.03M | -2.19M | -474.39K | -510.64K | -280.44K |
| Net Income | -84.03M | -142.88M | -71.98M | -53.96M | -52.56M | -82.87M | -31.04M | -19.49M |
| Net Income Ratio | -599.46% | -897.46% | -190.91% | -346.72% | -395.40% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| EPS Diluted | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| Weighted Avg Shares Out | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
| Weighted Avg Shares Out (Dil) | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue Estimates
MeiraGTx Announces Participation at Upcoming Investor Conferences
MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit
MeiraGTx to Present at the 2021 Barclays Global Healthcare Conference
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline
Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide
MeiraGTx: Early Stage Gene Therapy Developer For Eye Diseases
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports